Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $130.00.

Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience. WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasd ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Gilead Sciences (GILD) been one of those stocks this year?

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

Biomea Fusion appointed one of its board members, Mick Hitchcock, to succeed Thomas Butler as its interim chief executive. The change will help to ensure the company realizes its full potential ...